Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.63 |
| ▸ | PLK3 | Q9H4B4 | 8/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182116 | 0.90 | PLK1 (0.62) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL577969 | 0.81 | PLK1 (0.59) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL1371628 | 0.80 | PLK1 (0.59) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL4773618 | 0.80 | PLK1 (0.58) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL1370904 | 0.79 | PLK1 (0.82) | PLK1 | |
| SCHEMBL4195279 | 0.79 | PLK1 (0.57) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL4191139 | 0.78 | PLK1 (0.50) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL4404322 | 0.78 | PLK1 (1.00) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL13573204 | 0.78 | PLK1 (1.00) | PLK1PLK3CYP2C9CDK2IKBKE | |
| SCHEMBL577890 | 0.78 | PLK1 (0.64) | PLK1PLK3CYP2C9CDK2IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2015-02-05 | — | — | US | disclosed |
| US-8853244-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853244-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853244-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2027116-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| WO-2007139816-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139816-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | MAP3K1, MAP3K20, MAP3K2 | PLK1 18/4885PLK3 489/4885CYP2C9 4885/4885 |
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | PLK1 119/4885PLK3 469/4885CYP2C9 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.